citalopram has been researched along with zolpidem in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Madea, B; Musshoff, F; Schmidt, P | 1 |
| Bhatia, SC; Petty, F; Ramaswamy, S; Sattar, SP | 1 |
| Andersen, HF; Bech, P; Cialdella, P; Pedersen, AG; Tanghøj, P | 1 |
| Bomsien, S; Skopp, G | 1 |
| Asnis, GM; Bastani, B; Fava, M; Lydiard, B; Roth, T; Sheehan, D; Shrivastava, R | 1 |
| Crawford, B; Joish, VN; Lasch, K; Qiu, C; Rosa, K; Zhu, Y | 1 |
| Asnis, GM; Bastani, B; Fava, M; Lydiard, B; Roth, T; Sheehan, DV; Shrivastava, RK | 1 |
1 review(s) available for citalopram and zolpidem
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for citalopram and zolpidem
| Article | Year |
|---|---|
Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Hypnotics and Sedatives; Psychiatric Status Rating Scales; Psychometrics; Pyridines; Quality of Life; Sleep Initiation and Maintenance Disorders; Stereoisomerism; Suicide; Surveys and Questionnaires; Zolpidem | 2004 |
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Citalopram; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Psychometrics; Pyridines; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Young Adult; Zolpidem | 2009 |
Validation of the sleep impact scale in patients with major depressive disorder and insomnia.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Health Status Indicators; Humans; Hypnotics and Sedatives; Male; Middle Aged; Patient Satisfaction; Placebos; Pyridines; Quality of Life; Sleep; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Young Adult; Zolpidem | 2009 |
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Pyridines; Sleep; Sleep Initiation and Maintenance Disorders; Wakefulness; Zolpidem | 2011 |
12 other study(ies) available for citalopram and zolpidem
| Article | Year |
|---|---|
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Fatality caused by a combined trimipramine-citalopram intoxication.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depression; Drug Overdose; Drug Synergism; Fatal Outcome; Female; Humans; Hypnotics and Sedatives; Liver; Middle Aged; Pyridines; Suicide; Trimipramine; Zolpidem | 1999 |
Somnambulism due to probable interaction of valproic acid and zolpidem.
Topics: Bipolar Disorder; Citalopram; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Male; Middle Aged; Pyridines; Sleep Initiation and Maintenance Disorders; Somnambulism; Time Factors; Valproic Acid; Zolpidem | 2003 |
An in vitro approach to potential methadone metabolic-inhibition interactions.
Topics: Algorithms; Amitriptyline; Analgesics, Opioid; Atomoxetine Hydrochloride; Chromatography, Liquid; Citalopram; Clozapine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Isoenzymes; Kinetics; Methadone; Methylation; N-Methyl-3,4-methylenedioxyamphetamine; Oxidoreductases, N-Demethylating; Propylamines; Psychotropic Drugs; Pyridines; Pyrrolidines; Tandem Mass Spectrometry; Zolpidem | 2007 |